Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a blood vessel drug boost brain recovery after a hemorrhage?

NCT ID NCT07144956

Disease control Sponsor: Centre Hospitalier St Anne Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether adding cilostazol, a drug that improves blood flow, to standard nimodipine treatment helps people recover better after a brain aneurysm rupture. Researchers will enroll 630 adults in France within 96 hours of the bleed and follow them for 6 months. The goal is to see if the combination reduces disability and improves daily function.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Cilostazol (Pletal®) 100 mg tablets
What this could lead to
If it works, this could point toward a better recovery for people who survive a brain aneurysm rupture, reducing long-term disability.
What could go wrong
This is a phase 3 trial, but it's still early to know if adding cilostazol truly helps. The study is limited to France, and results may not apply to everyone. There is also a risk of side effects from the drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 630 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2025

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients admitted to an ICU with SAH related to a ruptured cerebral aneurysm occurring within the last 96 hours. * Aneurysm successfully secured by surgical clipping or endovascular coiling * Consent of the patient or, if not possible, from a proxy (emergency clause). * Registration in a national health care system Exclusion Criteria: * \- Precritical modified Rankin Scale (mRS) \> 2 * Nonaneurysmal SAH * Delayed \>96h admission after first symptoms of SAH * Coma defined by GCS of 3-5 with untreatable aneurysm will be excluded" * Known allergy to cilostazol * Pregnancy * Pre-existing major hepatic, renal, pulmonary or cardiac disease * Concomitant use of one other anti-platelet and/or anticoagulant agent * SAH diagnosed on Lumbar puncture with no evidence of blood on CT. * Tutelage or guardianship

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aneurysmal subarachnoid hemorrhage are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired aneurysmal subarachnoid hemorrhage subarachnoid hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aneurysmal subarachnoid hemorrhage

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.